EP0606222A1 - Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof - Google Patents

Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof

Info

Publication number
EP0606222A1
EP0606222A1 EP92916106A EP92916106A EP0606222A1 EP 0606222 A1 EP0606222 A1 EP 0606222A1 EP 92916106 A EP92916106 A EP 92916106A EP 92916106 A EP92916106 A EP 92916106A EP 0606222 A1 EP0606222 A1 EP 0606222A1
Authority
EP
European Patent Office
Prior art keywords
phe
gln
βala
trp
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92916106A
Other languages
German (de)
French (fr)
Inventor
Laura Quartara
Carlo Alberto Maggi
Riccardo Patacchini
Vittorio Pestellini
Antonio Giachetti
Federico Maria Arcamone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Menarini Industrie Farmaceutiche Riunite SRL
Original Assignee
Menarini Industrie Farmaceutiche Riunite SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT002231 external-priority patent/IT1251164B/en
Priority claimed from ITFI920128A external-priority patent/IT1258939B/en
Application filed by Menarini Industrie Farmaceutiche Riunite SRL filed Critical Menarini Industrie Farmaceutiche Riunite SRL
Publication of EP0606222A1 publication Critical patent/EP0606222A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Definitions

  • the invention refers to cyclic hexapeptide analogues of tachykinines of general formula (I)
  • R 1 H, linear or branched C 1-4 alkyl
  • R 3 H, natural or not natural amino acid free or protected side chain
  • R 3 ((H 2 ) n -R"
  • n 1, 2, 3, 4, 5
  • R" cyclooctyl, adamantyl, cyclohexyl, naphthyl
  • R" phenyl when n is other than 1
  • a 2 Trp, DTrp
  • W CO-NR' , CH 2 -NR'
  • R' H, CH 3 and their pharmaceutically acceptable salts with acids or organic or inorganic bases.
  • Tachykinins antagonist compounds of foraula (I) prove to be effective in the treatment of diseases where tachykinins play a pathogenic role, in particular in the treatment of arthritis , asthma, inflammations, tumor growth, gastrointestinal hypermotility, Huntington's disease, neuritis, neuralgia, migraine, hypertension, incontinence of urine, urticaria, carcinoid syndrome symptoms , influenza, and cold.
  • X stands for an amino acid characterizing each of the tachykinins.
  • tachykinins The pharmacological and biochemical results conveyed by the literature show that the biological activity of tachykinins is mediated, in mammals' tissues, by three distinct receptors at least, called NK-1, NK-2, NK-3. Natural tachykinines exhibit a different affinity with such three receptors. Highly potent tachykinins antagonists seem to be effective to reduce or antagonize pathological effects due to an excess of tachykinins in animals or man.
  • the first generation tachykinins antagonists described, for instance, in US-A-4,481,139 - scarcely selective - were followed by the second generation ones (EP-A-401,177; EP-A-347,802; GB-A- 2,216,529), more selective.
  • This invention refers to cyclic hexapeptide analogues of tachykinins of general formula (I)
  • R 1 H, linear or branched C 1-4 alkyl
  • R 3 natural or not natural amino acid free or protected side chain or
  • R 3 (CH 2 ) n -R"
  • n 1, 2, 3, 4, 5
  • R" cyclooctyl, adamantyl, cyclohexyl, naphthyl
  • R" phenyl when n is other than 1
  • a 2 Trp, DTrp
  • W CO-NR' , CH 2 -NR'
  • R' H, CH 3 and their pharmaceutically acceptable salts with acids or organic or inorganic bases.
  • linear or branched C 1-4 alkyl are selected in the group consisting of : methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl.
  • Natural amino acid is selected in the group consisting of : glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, serine. threonine, cysteine. tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine , arginine, histidine, in their L or D forms.
  • Not natural amino acid is selected in group consisting of ⁇ -alanine, D or L 2-aminoisobutyric acid, D or L 2,3-diaminopropionic acid, D or L norleucine, D or L alloisoleucine, D or L pyroglutamic acid, L or D 3-hydroxyproline, L or D 4-hydroxyproline, L or D phenylalanine substituted in the ortho, meta, or para position, L or D thienylalanine, L or D pyridylalanine, ⁇ (2- or 3- benzothienylalanine) , 1,2,3,4 tetrahydroisoquinoline-3-carboxyl acid.
  • amino acid chain protectors the following are given special consideration: Mbs, Mtr, NO2, Z, Tos, Pmc, For, Me, Ac. 2- Br-Z, 2-Cl-Z, Bzl, 2,6-dichloro-Bzl, SO3H, Fmoc, OMe, OBzl, OFm, ONp, OSu.
  • Protected side chain of a natural or not natural amino acid means, in particular, L or D Arg (Mbs), L or D Arg(Mtr), L or D Arg(NO 2 ), L or D Arg (Z), L or D Arg(Tos), L or D Arg(Pmc), L or D Trp(For), L or D Trp(Mts), L or D Tyr(Me), L or D Tyr(Ac), L or D Tyr(2-Br-Z), L or D Tyr(Bzl), L or D Tyr(2,6-dichloro-Bzl), L or D Tyr(SO 3 H), L or D Ser(Me), L or D Ser(Ac), L or D Ser(Bzl), L or D Ser(2,2-dichloro- Bzl), L or D Ser(SO3H), L or D Lys(Ac), L or D Lys(2-Br-Z), L or D Lys(2-Cl-Z), L or D Lys(Fmoc), L or D Ly
  • Substituted carboxamide group means a CONR 5 R 6 group, where R 5 and R 6 are equal or different and represent H or a linear or branched or cyclic alkyl, arylalkyl, aryl residue.
  • R 5 and R 6 together with the nitrogen atom can form a 5- or 6- terminal cycle including 4 or 5 carbon atoms or groups - CH 2 CH 2 NHCH 2 CH 2 -, CH 2 CH 2 N(CH 3 )CH 2 CH 2 -, -CH 2 CH 2 OCH 2 C H 2 -.
  • NR 5 R 6 can mean the residue of benzylamine, phenylethylamine even substituted with a halogen, 1- or 2- naphthylamine, cyclohexylamine, cyclooctylamine, adamantanamine, adamantyl-methylamine.
  • the cyclic peptide analogues covered by the present invention can be prepared by known synthetic techniques in the solid phase or in solution.
  • solid supports such as resin phenylacetamidomethyl (PAM) or the resin p- hydroxymethylphenoxymethyl (Hang), can be used.
  • PAM resin the amine function of amino acids is protected by the t- butyloxycabonyl group which can be selectively deprotected by trifluoracetic acid, whilst final deprotection - with simultaneous peptide detachment from the polymer support - is secured by anhydrous hydrofluoric acid.
  • the amino acid amine function is protected by the 9-fluorenylmethoxycarbonyl group (Fmoc), selectively deprotected by piperidine, whilst final deprotonation - with simultaneous peptide detachment from the polymer support - is secured by trifluoracetic acid.
  • Fmoc 9-fluorenylmethoxycarbonyl group
  • each amino acid is made to react in the form of free acid, in the presence of a suitable coupling agent , e . g. dicyclohexyl carbodiimide (DCC) , used with additives , if any, such as hydroxybenzothiazole (HOBT) or benzothiazolyl-N- oxytridlmethylaminophosphonium hexafluorophosphate (BOP) ; as an alternative, the amino acid can be made to react in the form of symmetric anhydride, activated ester, or according to any of the other methods described in literature. Amino acid coupling reaction completion can be ninhydrin tested, as described by E.T. Kaiser et al. , Anal.Biochem. , 1970, 34 , 595.
  • DCC dicyclohexyl carbodiimide
  • BOP benzothiazolyl-N- oxytridlmethylaminophosphonium hexafluorophosphate
  • Amino acids whose side chain is represented by the (CH 2 ) n -R" group can be synthesized by known organic chemistry techniques, such as, e.g., those described by Evans et al., J. Am. Chem. Soc., 112 (1990) 4011-4030; G.C. Barret, Chemistry and Biochemistry of the Amino Acids, Ed. G.C. Barret, Chapman & Hall, London, 1985, 246-296.
  • N- methoxymethylamide as per formula 2 is prepared from the corresponding N-protected amino acid.
  • the said amino acid is dissolved in methylene chloride; the solution is added with an equimolar amount of hydroxybenzotriazole and stirred for 20 minutes.
  • a sterically hindered tertiary amine e.g. diisopropylethylamine
  • the resulting mixture is kept under stirring for about 16 hours, after which it is washed with dilute aqueous HCl, with an NaHCO3 saturated solution, as well as with an NaCl saturated solution.
  • the desired product can be purified, e.g. by chromatography on silica gel.
  • N-methoxymethylamide as per formula 3 is reduced to produce the corresponding aldehyde as per formula 4.
  • the mixture is treated with a solution of acid potassium sdphate in water.
  • the product is then isolated by extraction, with
  • ether of the aqueous phase: for this purpose the ether phase is washed with dilute aqueous HCl, with NaCO 3 saturated solution, and with an NaCl saturated solution.
  • the aldehyde as per formula 4 is allowed to react with the compound as per formula 6, or with the N-terminal end of a pentapeptide chain bound to the resin by a ⁇ -alanine residue.
  • the initial Schiff base is reduced in situ, e.g. by sodium cyanoborohydride, to give a modified hexapeptide bound to the resin as per formula 7.
  • the suitably freeze-dried raw peptide is purified to homogeneity, e.g. by high pressure reversed-phase preparative chromatography.
  • Cyclic peptide synthesis can be obtained via cyclization in solution after preparation - according to one of the aforementioned methods, in the solution or solid phase - of the linear precursor of the desired cyclic peptide. Cyclization is performed with condensing agents and, if necessary, by activating the C-terminal carboxyl group of the cyclic precursor.
  • Carboxyl group deprotection is obtained by dissolving 300 mg benzyl ester in 40 mL aqueous 952 ethyl alcohol and adding the solution to a suspension of 100 mg Pd/C (10% Pd) in 6 mL 95% aqueous ethyl alcohol. The environment is saturated with hydrogen and the reacting mixture is kept under hydrogen environment for 2 hours. Then, the solution is filtered and dried.
  • Boc- ⁇ Ala-PAM resin (Bachem, Switzerland), equal to 0.45 mmoles of amine groups, is fed to a Labortec SP 640 semi-automatic peptide synthesis reactor.
  • the resin is washed as described in Table 1, cydes 6-7.
  • symmetric anhydride is prepared by dissolution of 0.48 g Boc-Phe-OH in 5 mL dichloromethane. The solution temperature is brought to 0oC and added with 0.9 mL of a 1M solution of dicyclohexylcarbodiimide in dichloromethane. After 15 minutes, dlcyclohexylurea is filtered and the resulting solution is added to the deprotected resin. The resin is kept under stirring at ambient temperature for 60 minutes (cycle 8). The procedure is completed by washing (cycles 9-12) and the reaction is ninhydrin-tested by the Kaiser method.
  • Boc-Trp-OH (0.548 g)
  • Boc-Gln-OH (0.443 g)
  • Boc- Asp(NHBzl)-OH (0.581 g).
  • Boc-Leu-H (0.242 g) dissolved in a dimethylformamide solution containing 5 mL 1% acetic acid is added to the resin; 5 mL of an NaBH 3 CN solution (70 mg) in a dimethylformamide solution containing 5 mL 1% acetic acid is allowed to drip under stirring for 40 minutes.
  • the resin is kept under stirring at ambient temperature for about 6 hours.
  • the procedure ends with washing (cycles 9-12) after which the ninhydrin test as by the Kaiser method is performed.
  • the Boc group is hydrolyzed with 50% TFA.
  • the resin is washed (cycles 9-12) and dried under vacuum, with the obtainment of 1.25 g dry product.
  • the product is placed in a Teflon reactor with 1.5 mL anisole and 0.75 mL dimethyl sulphide.
  • the mixture temperature is brought to -50oC and 15 mL hydrofluoric acid is distilled therein; then the mixture is kept under stirring for 60 min. in an ice bath.
  • Hydrofluoric acid is removed by nitrogen blowing.
  • the raw product is dried under suction for about 2 hours, is washed with ethyl ether (15 mL twice), extracted in 50% acetic acid (15 mL three times) and filtered in a fritted disc filter funnel to remove the exhaust resin.
  • the resdting solution is diluted with water and freeze-dried to yield 0.210 g raw product.
  • the cyclic peptide (ii) is purified by reversed-phase liquid chromatography and characterized by andyticd HPLC, Waters C18 Deltapack 3.9 ⁇ 150 mm column with an acetonitrile gradient containing 0.1% (v/v) trifluoracetic acid (phase B) vs. 0.1% (v/v) aqueous trifluoracetic acid (phase A), as well as 20 to 80% phase B, in 20 min., at a rate of 1 mL/min., with 210 nm UV monitoring.
  • Retention time (Rt) 10.6': chromatographic purity: >99%.
  • the ability of the peptides described in the present invention to interact with the neurokinine A receptor as agodsts or antagodsts was assessed through an in vitro test.
  • the preparation used for the test was characterized by the fact that the biological response produced by tachykinins and related peptides was exclusively determined by the neurokinine A receptor (receptor NK-2).
  • the sdd preparation consisted of isolated rabbit pulmonary artery affected by a dose dependent contraction brought about by tachykinins (Rovero et d., Neuropeptides, 1989, 13, 263-270).
  • the determination of peptide activity in the test preparation was based on the use of an NKA concentration (3 nm) causing a response equd to 45% of max.
  • the peptides considered herein were added to the preparation in growing concentrations. Their activity was assessed as inhibition of response to NKA.
  • the capacity of the peptides described herein to interact with the P substance receptor (receptor NK-1) as agonists or antagonists was assessed through an in vitro test, where the biological response produced by tachykinins and related peptides was exclusively determined at the SP receptor.
  • the test preparation consisted of isolated guinea pig ileum affected by a dose-dependent contraction (Lee et al. , Schnied. Arch. Pharmacol. , 1982, 318, 281-287) .
  • the determination of peptide activity in the test preparation was based on the use of an SP methyl ester concentration (10 nm) causing a response equal to 45% of max. response (S. Dion et al. , Life Sc ., 1987 , 41 , 2269-2278) .
  • the peptides considered herein were added to the preparation in growing concentrations. Their activity was assessed as inhibition of response to SP with satisfactory results .
  • the compounds covered by the invention are suitable for therapeutical administration to higher animals and nan by the parenteral. oral, dermic, nasal , inhalatory and sublingual ways, with pharmaceutical effects matching the described properties.
  • parenteral administration intravenous, intramuscular, intradermal
  • sterile solutions or freeze-dried preparations of the compounds are to be used.
  • oral administration preparations such as tablets, capsul es and syrups are convedently used.
  • Suitably dosed ointments and creams are utilizable by the dermic way.
  • the compounds to be used are respectively aqueous solutions, aerosol preparations, or capsul es.
  • Doses for therapeutical treatment range from 0.1 to 10 mg/kg body weight .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Analogues hexapeptidiques de tachyquinines et leurs sels pharmaceutiquement acceptables selon la formule générale (I), efficaces dans le traitement des maladies dans lesquelles les tachyquinines jouent un rôle pathogène, et notamment dans le traitement de l'arthrite, de l'asthme, des inflammations, de la croissance tumorale, de l'hypermotilité gastro-intestinale, de la chorée de Huntington, de la névrite, de la névralgie, des migraines, de l'hypertension, de l'incontinence urinaire, de l'urticaire, des symptômes de la carcinoïdose, de la grippe, et des rhumes.Hexapeptide analogues of tachyquinines and their pharmaceutically acceptable salts according to general formula (I), effective in the treatment of diseases in which tachyquinines play a pathogenic role, and in particular in the treatment of arthritis, asthma, inflammations, tumor growth, gastrointestinal hypermotility, Huntington's chorea, neuritis, neuralgia, migraines, hypertension, urinary incontinence, hives, symptoms of carcinoidosis, flu, and colds.

Description

CYCLIC HEXAPEPTIDES AS TACHYKININ ANTAGONISTS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
Field of the invention
The invention refers to cyclic hexapeptide analogues of tachykinines of general formula (I)
(I)
where
R1 = H, linear or branched C1-4 alkyl
R3 = H, natural or not natural amino acid free or protected side chain
or
R3 = ((H2)n-R"
wherein
n = 1, 2, 3, 4, 5
R" = cyclooctyl, adamantyl, cyclohexyl, naphthyl
R" = phenyl when n is other than 1
R" = a substituted carboxyamide group when n = 1, 2
A1 Gln, DGln
A2 = Trp, DTrp
A3 = Phe, DPhe
W = CO-NR' , CH2-NR'
where
R' = H, CH3 and their pharmaceutically acceptable salts with acids or organic or inorganic bases.
Tachykinins antagonist compounds of foraula (I) prove to be effective in the treatment of diseases where tachykinins play a pathogenic role, in particular in the treatment of arthritis , asthma, inflammations, tumor growth, gastrointestinal hypermotility, Huntington's disease, neuritis, neuralgia, migraine, hypertension, incontinence of urine, urticaria, carcinoid syndrome symptoms , influenza, and cold.
State of the Art
Tachykinins are a family of peptides characterized by the following common C-terminal sequence:
Phe-X-Gl y-Leu-Met-NH2
where X stands for an amino acid characterizing each of the tachykinins.
As far as mammals are concerned, the three tachykinins were called substance P (SP) (where X = Phe) , neurokinin A (NKA) (where X = Val) and neurokinin B (NKB) (where X = Val) and their neurotransmitter role, both at peripheral and central levels, was acknowledged (J.E. Maggio, Peptides. 1985. 6, 237-245 and P.C. Emson et al. , Neuropeptides and their peptidases, A.J. Turner and Ellis Horwood, England. 1987. PP. 87-106) .
The pharmacological and biochemical results conveyed by the literature show that the biological activity of tachykinins is mediated, in mammals' tissues, by three distinct receptors at least, called NK-1, NK-2, NK-3. Natural tachykinines exhibit a different affinity with such three receptors. Highly potent tachykinins antagonists seem to be effective to reduce or antagonize pathological effects due to an excess of tachykinins in animals or man. The first generation tachykinins antagonists described, for instance, in US-A-4,481,139 - scarcely selective - were followed by the second generation ones (EP-A-401,177; EP-A-347,802; GB-A- 2,216,529), more selective.
Research in the field is anyway aimed at singling out higher affinity and activity antagonists, free from agonist activity on other receptors, hence suitable for therapeutical use.
Detailed Description of the Invention
This invention refers to cyclic hexapeptide analogues of tachykinins of general formula (I)
(I) R1 A
where
R1 = H, linear or branched C1-4 alkyl
R3 = natural or not natural amino acid free or protected side chain or
R3 = (CH2)n-R"
where
n = 1, 2, 3, 4, 5
R" = cyclooctyl, adamantyl, cyclohexyl, naphthyl
R" = phenyl when n is other than 1
R" = a substituted carboxyamide group when n = 1, 2 A1 = Gln, DGln
A2 = Trp, DTrp
A3 = Phe, DPhe
W = CO-NR' , CH2-NR'
where
R' = H, CH3 and their pharmaceutically acceptable salts with acids or organic or inorganic bases.
According to this invention, linear or branched C1-4 alkyl are selected in the group consisting of : methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl.
Natural amino acid is selected in the group consisting of : glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, serine. threonine, cysteine. tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine , arginine, histidine, in their L or D forms.
Not natural amino acid is selected in group consisting of β-alanine, D or L 2-aminoisobutyric acid, D or L 2,3-diaminopropionic acid, D or L norleucine, D or L alloisoleucine, D or L pyroglutamic acid, L or D 3-hydroxyproline, L or D 4-hydroxyproline, L or D phenylalanine substituted in the ortho, meta, or para position, L or D thienylalanine, L or D pyridylalanine, β(2- or 3- benzothienylalanine) , 1,2,3,4 tetrahydroisoquinoline-3-carboxyl acid.
Among the amino acid chain protectors , the following are given special consideration: Mbs, Mtr, NO2, Z, Tos, Pmc, For, Me, Ac. 2- Br-Z, 2-Cl-Z, Bzl, 2,6-dichloro-Bzl, SO3H, Fmoc, OMe, OBzl, OFm, ONp, OSu.
Protected side chain of a natural or not natural amino acid means, in particular, L or D Arg (Mbs), L or D Arg(Mtr), L or D Arg(NO2), L or D Arg (Z), L or D Arg(Tos), L or D Arg(Pmc), L or D Trp(For), L or D Trp(Mts), L or D Tyr(Me), L or D Tyr(Ac), L or D Tyr(2-Br-Z), L or D Tyr(Bzl), L or D Tyr(2,6-dichloro-Bzl), L or D Tyr(SO3H), L or D Ser(Me), L or D Ser(Ac), L or D Ser(Bzl), L or D Ser(2,2-dichloro- Bzl), L or D Ser(SO3H), L or D Lys(Ac), L or D Lys(2-Br-Z), L or D Lys(2-Cl-Z), L or D Lys(Fmoc), L or D Lys(Z), L or D Lys(Tos), L or D Lys(Me), L or D Lys (Bzl), L or D Asp(OMe), L or D Asp(OBzl), L or D Asp(OFm), L or D Asp(ONp), L or D Asp(OSu), L or D Glu(OMe), L or D Glu(OBzl), L or D Glu(OFm), L or D Glu(ONp), L or D Glu(OSu).
Substituted carboxamide group means a CONR5R6 group, where R5 and R6 are equal or different and represent H or a linear or branched or cyclic alkyl, arylalkyl, aryl residue.
R5 and R6 together with the nitrogen atom can form a 5- or 6- terminal cycle including 4 or 5 carbon atoms or groups - CH2CH2NHCH2CH2-, CH2CH2N(CH3)CH2CH2 -, -CH2CH2OCH2C H2-.
In particular, NR5R6 can mean the residue of benzylamine, phenylethylamine even substituted with a halogen, 1- or 2- naphthylamine, cyclohexylamine, cyclooctylamine, adamantanamine, adamantyl-methylamine.
Among the compounds as per formula (I) of this invention, preference is given to R1 = isobutyl
A2 = Trp
R3 = (CH2)nC6H11, where n = 2, 3, 4, 5; (CH2)n-(1-naphthyl) , where n
= 2, 3, 4, 5; (CH2)n-(1-adamantyl) , where n = 1, 2, 3, 4, 5; (CH2)n- cyclooctyl, where n = 1, 2, 3, 4, 5; (CH2)n-CP6H5, where n = 2, 3,
4, 5; (CH2)n-CONHBzl, where n = 1, 2; (CH2)n-CONMeBzl, where n = 1.
2; (CH2)n-CONHCH2C6H11, where n = 1, 2; (CH2)n-CONMeCH2C6H11, where n = 1, 2; (CH2)n-CONH-CH2(1-adamantyl) , where n = 1, 2; (CH2)n-
CONMe-CH2(1-adamantyl) , where n = 1, 2.
In particular the following compounds are preferred:
cyclo(Leu-Cha-Gln-Trp-Phe-βAla)
cydo(Leu-Asp(NHBzl)-Gln-Trρ-Phe-βAla)
cyclo(Leu-Asρ(NMeBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu-Asp(NHCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu-Asp(NHeCH2C6H11) -Gln-Trp-Phe-βAla)
cyclo(Leu-Glu(NHBzl)-Gln-Trρ-Phe-βAla)
cyclo(Leu-Glu(NHeBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu-Glu(NHCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu-Clu(NHeCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu-Glu(NHCH2(1-adamantyl))-Gln-Trp-Phe-βAla)
cyclo(Leu-Glu(NMeCH2(1-adamantyl))-Gln-Trp-Phe-βAla)
cyclo(Leu-Asp(NHCH2(1-adamantyl))-Gln-Trp-Phe-βAla)
cyclo(Leu-Asp(NMeCH2(1-adamantyl))-Gln-Trp-Phe-βAla)
cyclo(Leu ψ [CH2NH]Asp(NHBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Asp(NMeBzl)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Asp(NHCH2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Asp(NMeCH2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Glu(NHBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Glu(NMeBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH] Glu(NHCH2C611)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Glu(NMeCH2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Glu(NHCH2(1-adamantyl) )-Gln-Trp -Phe-βAla) cyclo(Leu Ψ [CH2NH]Glu(NHCH2(1-adamantyl) )-Gln-Trp -Phe-βAla) cyclo(Leu Ψ [CH2NH]Asp(NHCH2(1-adamantyl) )-Gln-Trp -Phe-βAla) cyclo(Leu Ψ [CH2NH]Asp(NMeCH2(1-adamantyl) )-Gln-Trp -Phe-βAla) cyclo(Leu Ψ [CH2NMe]Asp(NHB zl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Asp(NMeBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Asp( HNCH 2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Asp(NMeCH2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NHBzl )-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Glu(NMeBzl)-Gln-Trρ-Phe-βAla)
cyclo(Leu Ψ [CH2NMe] Glu(NHCH 2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NMeCH2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NHCH2(1-adamantil) )-Gln-Trρ-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NMeCH2(1-adamantil) )-Gln-Trρ-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NHCH2(1-adamantil) )-Gln-Trρ-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NMeC H2(1-adamantil) )-Gln-Trρ-Phe-βAla) cyclo(Leu Ψ [CH2NH]Asp(OBzl)-Gln-Trρ-Phe-βAla)
cyclo(Leu Ψ [CH2NMe] Asp(OBzl)-Gln-Trρ-Phe-βAla)
cyclo(Leu Ψ [CH2NMe] Nal-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Cha-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Cha-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH ]Nal-Gln-Trp-Phe-βAla)
cyclo (Leu Ψ [CH2NMe]CH( (CH2)3Bzl)CO-Gln-Trp-Phe -βAla)
cyclo(Leu Ψ [CH2NH ]CH( (CH2)3Bzl)CO-Gln-Trp-Phe -βAla)
cyclo(Leu-NH-CH((CH2)3Bzl)CO-Gln-Trp-Phe-βAla)
The cyclic peptide analogues covered by the present invention can be prepared by known synthetic techniques in the solid phase or in solution. For the obtainment of linear peptides with the C-terminal carboxyl group in the form of free acid, solid supports such as resin phenylacetamidomethyl (PAM) or the resin p- hydroxymethylphenoxymethyl (Hang), can be used. In the case of PAM resin, the amine function of amino acids is protected by the t- butyloxycabonyl group which can be selectively deprotected by trifluoracetic acid, whilst final deprotection - with simultaneous peptide detachment from the polymer support - is secured by anhydrous hydrofluoric acid. In the case of the Hang resin, the amino acid amine function is protected by the 9-fluorenylmethoxycarbonyl group (Fmoc), selectively deprotected by piperidine, whilst final deprotonation - with simultaneous peptide detachment from the polymer support - is secured by trifluoracetic acid.
In both cases, the trifunctional amino acid side chains can be protected by the known methods described by literature. For the construction of the peptide chain on the insoluble polymer support, each amino acid is made to react in the form of free acid, in the presence of a suitable coupling agent , e . g. dicyclohexyl carbodiimide (DCC) , used with additives , if any, such as hydroxybenzothiazole (HOBT) or benzothiazolyl-N- oxytridlmethylaminophosphonium hexafluorophosphate (BOP) ; as an alternative, the amino acid can be made to react in the form of symmetric anhydride, activated ester, or according to any of the other methods described in literature. Amino acid coupling reaction completion can be ninhydrin tested, as described by E.T. Kaiser et al. , Anal.Biochem. , 1970, 34 , 595.
Amino acids with the R3=(CH2)n-CONR5R6 group as side chain can be synthesized, e.g. starting from the corresponding acid (where the α- amino and α-carboxyl groups have been pre-protected) , by condensation with the suitable HNR5R6 amine and the use of activators such as those currently employed in peptide chemistry (BOP, PyBOP, HOBT) .
Amino acids whose side chain is represented by the (CH2)n-R" group can be synthesized by known organic chemistry techniques, such as, e.g., those described by Evans et al., J. Am. Chem. Soc., 112 (1990) 4011-4030; G.C. Barret, Chemistry and Biochemistry of the Amino Acids, Ed. G.C. Barret, Chapman & Hall, London, 1985, 246-296.
As for the -CH2-NR'- bond, it is synthesized according to the procedure described by Sasaki and Coy, Peptides, 1987, 8, 119. Such a procedure was extended to the synthesis in the solid phase according to the Fmoc strategy, as described by Przewosny et al., Peptides, 1990, 370. Specifically (see scheme shown hereunder): N- methoxymethylamide as per formula 2 is prepared from the corresponding N-protected amino acid. The said amino acid is dissolved in methylene chloride; the solution is added with an equimolar amount of hydroxybenzotriazole and stirred for 20 minutes. Then, N-O-dimethylhydroxylamine.HCl dissolved in dichloromethane and added with an equimolar amount of a sterically hindered tertiary amine, e.g. diisopropylethylamine, is added to the said solution. The resulting mixture is kept under stirring for about 16 hours, after which it is washed with dilute aqueous HCl, with an NaHCO3 saturated solution, as well as with an NaCl saturated solution. The desired product can be purified, e.g. by chromatography on silica gel.
N-methoxymethylamide as per formula 3 is reduced to produce the corresponding aldehyde as per formula 4. e.g. with equimolar lithium aluminium hydride at 0ºC in an ether solution. On reaction completion, the mixture is treated with a solution of acid potassium sdphate in water.
The product is then isolated by extraction, with
ether, of the aqueous phase: for this purpose the ether phase is washed with dilute aqueous HCl, with NaCO3 saturated solution, and with an NaCl saturated solution.
B = Boc, Fmoc R2 = H; Me
The aldehyde as per formula 4 is allowed to react with the compound as per formula 6, or with the N-terminal end of a pentapeptide chain bound to the resin by a β-alanine residue. The initial Schiff base is reduced in situ, e.g. by sodium cyanoborohydride, to give a modified hexapeptide bound to the resin as per formula 7. After deprotection and detachment, performed as described above, the suitably freeze-dried raw peptide is purified to homogeneity, e.g. by high pressure reversed-phase preparative chromatography.
Cyclic peptide synthesis can be obtained via cyclization in solution after preparation - according to one of the aforementioned methods, in the solution or solid phase - of the linear precursor of the desired cyclic peptide. Cyclization is performed with condensing agents and, if necessary, by activating the C-terminal carboxyl group of the cyclic precursor.
EXAMPLE
Preparation of the cyclic peptide :
cyclo(LeuΨ [CH2NH]Asp(NHBzl)-Cln-Trp-Phe-βAla) (ii)
a) Synthesis of the linear peptide having the following sequence: H-LeuΨ [CH2NH]Asp(NHBzl)-Gln-Trp-Phe-βAla-OH (i)
Synthesis of Boc-Asp(NHBzl)-OH: 323 g Boc-Asp-OBzl (Novabiochem, Switzerland) is solubilized in 70 mL dioxane; then the solution is added with 530 mg BOP, 37μL DIEA and, finally. 107 mg benzylamine. After 3 hours, the reaction mixture is dried and the residue is purified by chromatography on Mterck silica gel 60 (mesh 70-230) with ethyl acetate-1/n-hexane-1 (v/v), as eluent, Rf = 0.3.310 mg yield. Carboxyl group deprotection is obtained by dissolving 300 mg benzyl ester in 40 mL aqueous 952 ethyl alcohol and adding the solution to a suspension of 100 mg Pd/C (10% Pd) in 6 mL 95% aqueous ethyl alcohol. The environment is saturated with hydrogen and the reacting mixture is kept under hydrogen environment for 2 hours. Then, the solution is filtered and dried.
3.0 g Boc-βAla-PAM resin (Bachem, Switzerland), equal to 0.45 mmoles of amine groups, is fed to a Labortec SP 640 semi-automatic peptide synthesis reactor. The resin is washed as described in Table 1, cydes 6-7.
For resin coupling to the subsequent amino acid, symmetric anhydride is prepared by dissolution of 0.48 g Boc-Phe-OH in 5 mL dichloromethane. The solution temperature is brought to 0ºC and added with 0.9 mL of a 1M solution of dicyclohexylcarbodiimide in dichloromethane. After 15 minutes, dlcyclohexylurea is filtered and the resulting solution is added to the deprotected resin. The resin is kept under stirring at ambient temperature for 60 minutes (cycle 8). The procedure is completed by washing (cycles 9-12) and the reaction is ninhydrin-tested by the Kaiser method. In case of a negative response, the Boc group is hydrolyzed with 50% TFA (cycles 1-4), before the subsequent amino acid coupling, which takes place according to the described procedure. The following residues are made to react in the same order, in the quantities indicated in brackets: Boc-Trp-OH (0.548 g), Boc-Gln-OH (0.443 g). Boc- Asp(NHBzl)-OH (0.581 g). After deprotection, Boc-Leu-H (0.242 g) dissolved in a dimethylformamide solution containing 5 mL 1% acetic acid is added to the resin; 5 mL of an NaBH3CN solution (70 mg) in a dimethylformamide solution containing 5 mL 1% acetic acid is allowed to drip under stirring for 40 minutes. The resin is kept under stirring at ambient temperature for about 6 hours. The procedure ends with washing (cycles 9-12) after which the ninhydrin test as by the Kaiser method is performed. In case of a negative response, the Boc group is hydrolyzed with 50% TFA. Then, the resin is washed (cycles 9-12) and dried under vacuum, with the obtainment of 1.25 g dry product. For peptide detachment from the resin, the product is placed in a Teflon reactor with 1.5 mL anisole and 0.75 mL dimethyl sulphide. The mixture temperature is brought to -50ºC and 15 mL hydrofluoric acid is distilled therein; then the mixture is kept under stirring for 60 min. in an ice bath. Hydrofluoric acid is removed by nitrogen blowing. The raw product is dried under suction for about 2 hours, is washed with ethyl ether (15 mL twice), extracted in 50% acetic acid (15 mL three times) and filtered in a fritted disc filter funnel to remove the exhaust resin. The resdting solution is diluted with water and freeze-dried to yield 0.210 g raw product. Findly, the peptide is purified by reversedphase liquid chromatography and characterized by analytical HPLC, Waters C18 Deltapack 3-9 x 150 mm column with an acetonitrlle gradient containing 0.1% (v/v) trifluoracetic acid (phase B) vs. 0.1% (v/v) aqueous trifluoracetic acid (phase A), as well as 20 to 80% phase B, in 20 minutes, at a rate of 1 mL/min., with 210 nm UV monitoring. Retention time (Rt) = 9-2'; chromatographic purity: > 99%.
b) Cyclization of the above said peptide (1) into the cyclic peptide cyclo(Leu [CH2NH]Asp(NHBzl) -Gln-Trp-Phe-βAla (ii)
65 mg product (i) is dissolved in 35 mL DMF. The solution is added with 47 mg PyBOP, then 32 μL DIEA. The resulting solution is kept under stirring at ambient temperature for 2 hours , then DMF is removed under vacuum and the resul ting mixture freeze-dried. The cyclic peptide (ii) is purified by reversed-phase liquid chromatography and characterized by andyticd HPLC, Waters C18 Deltapack 3.9 × 150 mm column with an acetonitrile gradient containing 0.1% (v/v) trifluoracetic acid (phase B) vs. 0.1% (v/v) aqueous trifluoracetic acid (phase A), as well as 20 to 80% phase B, in 20 min., at a rate of 1 mL/min., with 210 nm UV monitoring.
Retention time (Rt) = 10.6': chromatographic purity: >99%.
By the procedure described above and using suitable reagents, the following peptides are obtained:
H-Leu Ψ [CH2NH]Asp(NH-CH2-(1-adamantyl))-Gln-Trp-Phe-βAla-OH retention time (Rt) = 9.5'; chromatographic purity: > 99%.
H-LeuΨ[CH2NH]Asp(NH-CH2-C6H11)-Gln-Trp-Phe-βAla-OH
retention time (Rt) = 9.0'; chromatographic purity: > 99%.
H-Leu Ψ [ CH2NH ]Glu(NHBzl)-Gln-Trp-Phe-βAla-OH retention time (Rt) = 9.3'; chromatographic purity: > 99%.
H-LeuΨ[CH2NH]Glu(NMBzl)-Glu-Trp-Phe-βAla- OH
retention time (Rt) = 9.8'; chromatographic purity: > 99%.
H-LeuΨ[CH2NH]CH((CH2)3Bzl) -CO-Gln-Trp-Phe -βAla-OH
retention time (Rt) = 11 '; chromatographic purity: > 99%.
H-Leu-Asp(NHBzl) -Gln-Trp-Phe -βAla-OH
retention time (Rt) = 9.6'; chromatographic purity: > 99%'
H-Leu- Cha-Gln- Trp-Phe-βAla- OH
retention time (Rt) = 9.8'; chromatographic purity: > 99%.
H-LeuΨ[CH2NH]Asp(OBzl)-Gln-Trp-Phe-βAla- OH
retention time (Rt) = 10.7';chromatographic purity: > 99%
H-LeuΨ[CH2NH]Leu-Gln-Trp -DPhe-βAla- OH
retention time (Rt) = 7.7'; chromatographic purity: > 99%
H-LeuΨ[CH2NH]Lys(Z)-Gln-Trp-Phe- βAla- OH
retention time (Rt) = 8.9'; chromatographic purity: > 99% H-Leu Ψ [CH2NH]Cha-Gln-Trp-Dphe-βAla-OH
retention time (Rt) = 9.0 ; chromatographic purity: > 99%
H-Leu Ψ [CH2NH]Nal-Gln-Trp-Phe-βAla-OH
retention time (Rt) = 9.9' ; chromatographic purity: > 99%
H-Leu Ψ [ CH2NMe]Cha-Gln-Trp-Phe-βAla-OH
retention time (Rt) = 11.1' ; chromatographic purity: > 99%
Which are cyclized into the following cyclic peptides : cyclo(Leu
[CH2NH]Asp(NH 2-(1-adamantyl) )-Gln-Trp-Phe-βAla)
retention time (Rt) = 11.0' ; chromatographic purity: > 99%.
cyclo(Leu Ψ [CH2NH]ASp(NH-CH2-C6H11)-Trp-Phe-βAla)
retention time (Rt) = 11.2'; chromatographic purity: > 99%.
cyclo(Leu Ψ [CH2NH]Glu(NHBzl)-Gln-Trp-Phe-βAla)
retention time (Rt) = 10.0'; chromatographic purity: > 99%.
cyclo(LeuΨ [CH2NH]Asp(NMeBzl)-Gln-Trp-Phe-βAla)
retention time (Rt) = 12.5'; chromatographic purity: > 99%.
cyclo(Le uΨ [CH2NH]CH((CH2)3Bzl)-CO-Gln-Trp-Phe-βAla)
retention time (Rt) = 13.5'; chromatographic purity: > 99%.
cyclo(Leu-Asp(NHBzl)-Gln-Trp-Phe-βAla)
retention time (Rt) = 10.6'; chromatographic purity: > 99%.
cyclo(Leu-Cha-Gln-Trp-Phe-βAla)
retention time (Rt) = 11.2' ; chromatographic purity: > 99%.
cycl o(Le u Ψ [CH2NH]Asp(OBzl)-Gln-Trp-Phe-βAla
retention time (Rt) = 9.8' ; chromatographic purity: > 99%
cyclo(Leu Ψ [CH2NH]Leu-Gln-Trp-DPhe-βAla)
retention time (Rt) = 9.4' ; chromatographic purity: > 99% cycl o(Le u Ψ [CH2NH]Lys(Z)-Gln-Trp-Phe-βAla)
retention time (Rt) = 10.7' ; chromatographic purity: > 99%cycl o (Leu Ψ [ CH2NH] Cha-Trp-Phe- βAla)
retention time = (Rt) = 11.1'; chroaatograpdc purity: > 99 %cycl o(LeuΨ [CH2NH]Nal-Gln-Trp-Phe-βAla)
retention time (Rt) = 13.0'; chromatographic purity: > 99%
cyclo (leuΨ [CH2NMe]Cha-Gln-Trp-Phe-βAla)
retention time (Rt) = 12.2'; chromatographic purity: > 99%
BIOLOGICAL ACTIVITY
The ability of the peptides described in the present invention to interact with the neurokinine A receptor as agodsts or antagodsts was assessed through an in vitro test. The preparation used for the test was characterized by the fact that the biological response produced by tachykinins and related peptides was exclusively determined by the neurokinine A receptor (receptor NK-2). The sdd preparation consisted of isolated rabbit pulmonary artery affected by a dose dependent contraction brought about by tachykinins (Rovero et d., Neuropeptides, 1989, 13, 263-270). The determination of peptide activity in the test preparation was based on the use of an NKA concentration (3 nm) causing a response equd to 45% of max. response. The peptides considered herein were added to the preparation in growing concentrations. Their activity was assessed as inhibition of response to NKA. The capacity of the peptides described herein to interact with the P substance receptor (receptor NK-1) as agonists or antagonists was assessed through an in vitro test, where the biological response produced by tachykinins and related peptides was exclusively determined at the SP receptor. The test preparation consisted of isolated guinea pig ileum affected by a dose-dependent contraction (Lee et al. , Schnied. Arch. Pharmacol. , 1982, 318, 281-287) . The determination of peptide activity in the test preparation was based on the use of an SP methyl ester concentration (10 nm) causing a response equal to 45% of max. response (S. Dion et al. , Life Sc ., 1987 , 41 , 2269-2278) . The peptides considered herein were added to the preparation in growing concentrations. Their activity was assessed as inhibition of response to SP with satisfactory results .
The compounds covered by the invention are suitable for therapeutical administration to higher animals and nan by the parenteral. oral, dermic, nasal , inhalatory and sublingual ways, with pharmaceutical effects matching the described properties. In case of parenteral administration (intravenous, intramuscular, intradermal ) , sterile solutions or freeze-dried preparations of the compounds are to be used. In case of oral administration, preparations such as tablets, capsul es and syrups are convedently used. Suitably dosed ointments and creams are utilizable by the dermic way. In case of nasal instillation, inhalation, and sublingual administration , the compounds to be used are respectively aqueous solutions, aerosol preparations, or capsul es.
Doses for therapeutical treatment range from 0.1 to 10 mg/kg body weight .

Claims

1. Cyclic hexapeptides of general formula
(I)
where
R1 = H, linear or branched C1-4 alkyl
R3 = natural or not natural amino acid free or protected side chain R3 = (CH2)n-R"
where
n = 1, 2, 3, 4, 5
R" = cyclooctyl, adamantyl, cyclohexyl, naphthyl
R" = phenyl when n is other than 1
R" = a substituted carboxyamide group when n = 1, 2
A1 = Gln, DGln
A2 = Trp, DTrp
A3 = Phe, DPhe
W = CO-NR', CH2-NR'
wherein
R' = H, CH3 and their pharmaceutically acceptable salts with acids or organic or organic bases.
2. Cyclic hexapeptides as per claim 1, wherein:
linear or branched C1-4 alkyl are selected in the group consisting of: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl.
The natural amino acid is selected in the group consisting of : glycine, alanine, valine, leucine, isoleucine, proline, phenylalnine, tryptophan, methionine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, dstidine, in their L or D forms.
Not naturd aaino acid is selected in the group consisting of: β- alanine, D or L 2-aminoisobutyric acid, D or L 2,3-daminoproρionic acid, D or L norleucine, D or L alloisoleucine, D or L pyroglutamic acid, L or D 3-hydroxyproline, L or D 4-hydroxyproline, L or D phenyldanine substituted in the ortho, meta, or para position, L or D thienylalanine, L or D pyridylalanine, β(2- or 3- benzothienyldanine), 1,2,3,4 tetrahydroisoquinoline-3-carboxyl aci d.
Amino acid chain protector is selected in the group consisting of : Mbs, Mtr, NO2, Z, Tos, Pmc, For, Me, Ac, 2-Br-Z, 2-Cl-Z, Bzl, 2,6- dichloro-Bzl, SO3H, Fmoc, OMe, OBzl, OFm, ONp, OSu.
3. Hexapeptides as per claim 2, wherein the protected side chain of a natural or not natural amino acid is selected in the group consisting of : L or D Arg (Mbs), L or D Arg(Mtr), L or D Arg(NO2), L or D Arg (Z), L or D Arg(Tos), L or D Arg(Pmc), L or D Trp(For), L or D Trρ(Mts), L or D Tyr(Me), L or D Tyr(Ac), L or D Tyr(2-Br-Z), L or D Tyr(Bzl), L or D Tyr(2,6-dichloro-Bzl), L or D Tyr(SO3H), L or D Ser(Me), L or D Ser(Ac), L or D Ser(Bzl), L or D Ser(2,2-dichloro- Bzl), L or D Ser(SO3H), L or D Lys(Ac), L or D Lys(2-Br-Z), L or D Lys(2-Cl-Z), L or D Lys(Fmoc), L or D Lys(Z), L or D Lys(Tos), L or D Lys(Me), L or D Lys (Bzl), L or D Asp (OMe) , L or D Asp(OBzl), L or D Asp(OFm) , L or D Asp(ONp) , L or D Asp(OSu) , L or D Glu(OMe) , L or D Glu(OBzl), L or D Glu(OFm), L or D Glu(ONp), L or D Glu(OSu),
4. Cyclic hexapeptide as per claim 3. wherein R1 = isobutyl.
5. Cyclic hexapeptide as per claim 4, wherein A2 = Trp.
6. Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-C6H11' where n = 2, 3, 4, 5.
7. Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-(1- naphthyl), where n = 2, 3, 4, 5.
8. Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-(1- adamantyl), where n = 1, 2, 3, 4, 5.
9. Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n- cyclooctyl, where n =1, 2, 3, 4, 5.
10.Cydic hexapeptide as per claim 5, wherein R3 = (CH2)n-C6H5, where n = 2, 3, 4, 5.
11. Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-CONHBzl, where n = 1, 2.
12.Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-CONMeBzl, where n = 1, 2.
13. Cyclic hexapeptide as per claim 5 , wherein R3 = (CH2)n- CONHCH2C6H11, where n = 1, 2.
14. Cyclic hexapeptide as per claim 5 , wherein R3 = (CH2)n- CONMeCH2C6H11, where n = 1, 2.
15. Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-CONH- CH2(1-adamantyl) , where n = 1, 2.
16.Cyclic hexapeptide as per claim 5, wherein R3 = (CH2)n-CONMe- CH2(1-adamantyl) , where n = 1 , 2.
17. Cyclic hexapeptide of general formula (I) , as per claim 1 , selected in the group consisting of :
cyclo(Leu-Cha-Gln-Trp-Phe-βAla)
cyclo(Leu-Asp(NHBzl)-Gln-Trρ-Phe-βAla)
cyclo (Leu-Asp(NMeBzl)-Gln-Trp-Phe-βAla)
cyclo( Leu-Asp(NHCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu-Asp(NMeCH2C6H11) -Gln-Trp-Phe-βAla)
cyclo (Leu-Glu(NHBzl)-Gln-Trρ-Phe-βAla)
cyclo (Leu-Glu (NMeBzl ) -Gln-Trp-Phe-βAla)
cyclo( Leu-Glu(NHCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo (Leu-Glu(NMeCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo( Leu-Glu(NHCH2(1-adamantyl) )-Gln-Trp-Phe-βAla)
cyclo (Leu-Glu(NMeCH2(1-adamantyl) )-Gln-Trp-Phe-βAla)
cyclo (Leu-Asp(NHCH2(1-adamantyl) )-Gln-Trp-Phe-βAla)
cyclo (Leu-Asp(NMeCH2(1-adamantyl) )-Gln-Trp-Phe-βAla)
18. Cyclic hexapeptide , of general formula (I ) , as per claim 1 , selected in the group consisting of :
cyclo(Leu Ψ [CH2NH]Asp(NHBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Asp(NMeBzl) -Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Asp (NHCH2C6H11 ) -Gln-Trp-Phe-βAla)
cydo(Leu Ψ [CH2NH]Asp(NMeCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo (Leu Ψ [CH2NH]Glu(NHBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Glu(NMeBzl )-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Glu(NHCH2C6H11)-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Glu(NMeCH2 C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH]Glu(NHCH2(1-adamantyl) )-Gln-Trp -Phe-βAla) cyclo(Leu Ψ [CH2NH]Glu(NMeCH2(1-adaaantyl) )-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH ]Asp(NHCH2(1- adamantyl))-Gln-Trp -Phe-βAla) cyclo(Leu Ψ [CH2NH ]Asp(NMeCH2( 1 -adamantyl ) )-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NH]Asp(OBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH ]Cha-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NH ]Nal-Gln-Trp-Phe-βAla)
19. Cyclic hexapeptide of general formula (I) , as per claim 1 , selected in the group consisting of:
cyclo(Leu Ψ [CH2NMe]Asp(NHBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Asp(NMeBzl)-Gln-Trρ-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Asp(NHCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Asp(NMeCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Glu(NHBzl) -Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Glu(NMeBzl) -Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Glu(NHCH2C6H11 ) -Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Glu(NMeCH2C6H11)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Glu(NHCH2 ( 1-adamantyl) )-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Glu(NMeCH2(1-adamantyl) )-Gln-Trρ-Phe-βAla) cyclo(Leu Ψ [CH2NMe]Asp(NHCH2(1-adamantyl) )-Gln-Trp-Phe-βAla)cyclo(LeuΨ [CH2NMe]Asp(NMeCH2(1-adamantyl) )-Gln-Trp-Phe-βAla) cyclo(Leu Ψ [CH2NMe]CH((CH2)3Bzl)CO-Gln-Trp-Phe -βAla)
cyclo(Leu Ψ [CH2NMe]Asρ(OBzl)-Gln-Trp-Phe-βAla)
cyclo(Leu Ψ [CH2NMe]Nal -Gln-Trp-Phe-βAla) cyclo( Leu Ψ [CH2NMe]Cha-Gln-Trp-Phe-βAla)
20. Cyclic hexapeptide, generd formula (I) , as per claim 1, selected among those of the group formed by
cyclo( Leu Ψ [CH2NH]CH( (CH2)3Bzl)CO-Gln-Trp-Phe-βAla)
cyclo( Leu-NH-CH( (CH2)3Bzl)CO-Gln-Trp-Phe-βAla)
21.Peptide preparation process as per claim 1 including peptide chain solid phase synthesis from C-terminal end to N-terminal end on an insoluble polymer support, the introduction of the iminomethylene bond, the subsequent detachment from polymer support by hydrolysis in anhydrous hydrofluoric acid and the linear peptide cyclization in polar organic solvents.
22.Peptide preparation process as per claim 1 including peptide chain solid phase synthesis from C-terminal end to N-terminal on an insoluble polymer support, the introduction of the iminomethylene bond, the subsequent detachment from polymer support by hydrolysis in trifluoracetic acid and the linear peptide cyclization in polar organic solvents.
23.Pharmaceutical compositions for the treatment of diseases where tachyquinines play a pathogenic role.
EP92916106A 1991-08-08 1992-08-03 Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof Withdrawn EP0606222A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT002231 IT1251164B (en) 1991-08-08 1991-08-08 New cyclic hexa:peptide derivs., are tachy:kinin antagonists - useful for treating arthritis, asthma, inflammation, tumours, gastrointestinal hyper motility, migraine, hypertension, etc.
ITMI912231 1991-08-08
ITFI920128 1992-06-19
ITFI920128A IT1258939B (en) 1992-06-19 1992-06-19 Linear or cyclic hexapeptide analogues of tachyquinine and their pharmaceutically acceptable salts, their preparation and pharmaceutical compositions containing them
PCT/EP1992/001760 WO1993003059A1 (en) 1991-08-08 1992-08-03 Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
EP0606222A1 true EP0606222A1 (en) 1994-07-20

Family

ID=26330507

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92916106A Withdrawn EP0606222A1 (en) 1991-08-08 1992-08-03 Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof

Country Status (5)

Country Link
EP (1) EP0606222A1 (en)
JP (1) JPH06509571A (en)
AU (1) AU2387592A (en)
PT (1) PT100764A (en)
WO (1) WO1993003059A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283171B1 (en) * 1996-03-01 1998-04-16 Interdipartimentale Di Ricerca SOLUBLE COMPOUNDS ANTAGONISTS OF TACHYCININS THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
IT1304888B1 (en) * 1998-08-05 2001-04-05 Menarini Ricerche Spa MONOCYCLIC ACTION COMPOUNDS NK-2 ANTAGONIST AND FORMULATIONS THAT CONTAIN
IT1307809B1 (en) * 1999-10-21 2001-11-19 Menarini Ricerche Spa BASIC MONOCYCLIC COMPOUNDS WITH NK-2 ANTAGONIST ACTION, MANUFACTURING PROCESSES AND FORMULATIONS CONTAINING THEM.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3915361A1 (en) * 1989-05-11 1990-11-15 Merck Patent Gmbh CYCLO PEPTIDE
ZA906188B (en) * 1989-08-10 1991-06-26 Merrell Dow Pharma Cyclic neurokinin a antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9303059A1 *

Also Published As

Publication number Publication date
AU2387592A (en) 1993-03-02
WO1993003059A1 (en) 1993-02-18
PT100764A (en) 1994-02-28
JPH06509571A (en) 1994-10-27

Similar Documents

Publication Publication Date Title
EP4092038A1 (en) Opioid agonist peptides and uses thereof
EP1179537B1 (en) Solid phase peptide synthesis method
JP2000510453A (en) Compounds having growth hormone releasing properties
US20040122013A1 (en) Analogs of nocicettin
EP0401177B1 (en) Synthetic peptide antagonists of neurokinin a, salts thereof and respective preparation processes
US5731285A (en) Tachiquinine antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
CA2405704C (en) Bombesin analogs for treatment of cancer
EP0606222A1 (en) Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof
EP0636146B1 (en) Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
CA2182486C (en) Cyclic neurokinin a antagonists
JP2001505216A (en) Bradykinin B (2) Peptide agonist of receptor
CA2405724C (en) Substance p analogs for the treatment of cancer
US6596692B1 (en) Substance P analogs for the treatment of cancer
EP0541662A1 (en) Synthetic peptides that antagonize neurokinin a, their salts and their manufacturing processes.
WO1994006453A1 (en) Bradykinin antagonists containing aliphatic amino acids in the 5-position
US6989371B1 (en) Bombesin analogs for treatment of cancer
AU700904B2 (en) Amino acids for making betides and methods of screening and making betide libraries
US20060160989A1 (en) Polypeptide useful as antiallergic/antiasthmatic activity, methods for the preparation thereof, pharmaceutical compositions containing such polypeptide and use thereof
EP1348714A1 (en) Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19951002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960705